On July 22, the State Food and Drug Administration announced that Duzheng Biological was authorized to produce pantoprazole enteric-coated tablets for BE research CRO (Xianning Central Hospital is responsible for clinical practice, leading medicine is responsible for recruitment and SMO service, farmar ke data implementation data management and statistical analysis), entrusted by Hunan Jiudan Pharmaceutical Co., LTD. At present, our company provides clinical research services for the two pantoprazole sodium enteric-coated tablets approved in China.

 Pantoprazole is a commonly used drug for the treatment of peptic ulcer and other diseases. It belongs to the benzimidazoles proton pump inhibitors (PPI), and its action and mechanism are the same as omeprazole, but its binding selectivity with proton pump is higher, and it is more stable, and is generally believed to be stronger than omeprazole. According to relevant data, the retail and medical terminal market in 2019 pantoprazole oral preparation sales of about 2.5 billion yuan.

Duzheng Biotech is committed to providing the whole chain of BE/PK and Phase ⅰ - ⅳ clinical trial services to drug r&d institutions worldwide, including medical affairs, clinical research, data management and statistical analysis, registration affairs, policy consulting, etc. With "scientific, professional, standardized and efficient" services to help bid to promote the product listing process. At present, many new drugs and generic drugs are in clinical development.

In the future, the company will continue to uphold the concept of "innovation and truth-seeking", take customers as the center, provide high-quality and efficient clinical research "one-stop" service for domestic and foreign partners, and help the development of China's pharmaceutical industry!